Research & Development
MBio partners with DARPA to seek FDA approval of LightDeck Platform in identifying highly contagious individuals early
7 April 2020 -

Testing company MBio Diagnostics stated on Monday that it plans to accelerate progress of its LightDeck platform to developing human host-response biomarker assays in identifying gravely ill or highly contagious individuals early in the disease cycle towards US FDA approval under an expanded scope contract with the US Defense Advanced Research Projects Agency (DARPA).

Since February 2018. MBio has partnered with DARPA on 'Point-of-care Monitoring of the Host-Pathogen Interaction During Infection'.

An additional USD1.5m in funding will allow MBio to augment its clinical and regulatory capabilities, in anticipation of the company seeking first FDA approvals for the LightDeck platform across military and other medical settings.

MBio's patented LightDeck platform incorporates low-cost, multiplexed cartridges with fluorescent readers and intuitive software, with the ability to measure more than 50 analytes in a single cartridge. Hence by measuring the specific blood biomarkers associated with the human immune response, it may be possible to identify infected individuals early before symptoms emerge, including COVID-19 disease symptoms.

Login
Username:

Password: